TenNor Therapeutics Announces $25 Million Series B Financing to Advance TNP-2092 Clinical Trials

Release Date:2016-09-20 07:47     Hits:1148

TenNor Therapeutics today announced a $25 million Series B financing led by Northern Light Venture Capital. Joining this round were current investors Frontline BioVentures, WuXi PharmaTech Healthcare Fund I, Oriza Venture Capital and Relativity Healthcare Fund. Proceeds will be used to advance new antibiotics into the late-stage of clinical development. For full news release please see: http://www.prnewswire.com/news-releases/tennor-therapeutics-announces-25-million-series-b-financing-to-advance-tnp-2092-clinical-trials-300329942.html.